...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

My original reply was removed for a violation.

hahahahahaha......you got me there narmac.  :)

I can't say I disagree with you on any point. With the expectations set up by Don in 2013 and continuously up to about 2 years ago I had expected value creation for shareholders by 2017. We don't even have enough value created to do a NASDAQ at this stage.

The scientists seem to  keep having fun and making progress but not to the stage of any investtment value.

It's going to be a long wait IMHO.

GLTA

Toinv

Share
New Message
Please login to post a reply